Medical Crossfire®:Exploring the Modern Management of Acute Lymphoblastic Leukemia from AYA to Adult
CHAIR: Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
- Utilize risk stratification strategies to develop appropriate treatment plans for patients with ALL
- Assess the importance of minimal residual disease and its role in determining prognosis as well as in treatment planning
- Review the safety and efficacy of emerging therapies in the management of ALL
Acknowledgment of Commercial Support
This activity is supported by educational grants from Amgen, Jazz Pharmaceuticals, Servier Pharmaceuticals LLC, and Takeda Oncology.